Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Химиотерапия рака шейки матки: роль топотекана в борьбе за увеличение выживаемости и улучшение качества жизни пациентов
Химиотерапия рака шейки матки: роль топотекана в борьбе за увеличение выживаемости и улучшение качества жизни пациентов
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Saslow D, Castle PE, Cox T et al. American Cancer Society Guidelinefor human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57: 7–28.
2. Schiffman M, Kjaer SK. Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 14.
3. Онкология. Национальное руководство. Под ред. акад. В.И.Чисова. М.: Гэотар-Медиа, 2008.
4. Fiorica J, Holloway R, Ndubisi B et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gyn Oncol 2002; 85 (1): 89–94.
5. Новик В.И. Эпидемиология рака шейки матки, факторы риска, скрининг. Практ. онкол. 2002; 3 (3).
6. Tiersten AD, Selleck MJ, Hershman DL et al. Phase II study of topotecan and paclitaxel for persistent, or metastatic cervical cancer. Gyn Oncol 2004; 92: 635–8.
7. Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 2003; 9 (5): 425–32 (Review).
8. Thigpen T, Shingleton H, Homesley H et al. Cis-dichlorodiammineplatinum (II) in the treatment of gynecologic malignancies: Phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep 1979; 63: 1549–55.
9. Lorusso D, Pietragalla A, Mainenti S et al. Review role of topotecan in gynaecological cancers: Current indications and perspectives. Crit Rev Oncol Hematol 2009; 17 [Epub ahead of print].
10. McGuire WP, Blessing JA, Bookman MA et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian сarcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 1062–7.
11. Randall-Whitis LM, Monk BJ. Topotecan in the management of cervical cancer. Expert Opin Pharmacother 2007; 8: 227–36.
12. Long HJ 3rd, Bundy Bn, Grendys EC JR et al. Randomized phase III trial of Cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol 2005; 23: 4623–33.
13. Monk BJ, Huang HQ, Cella D et al. Quality of life outcomes from a randomized phase III trial of Cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4617–25.
14. McCabe F et al. Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest 1994; 12: 308–13.
15. Bence A et al. Evaluation of topotecan cytotoxicity and topoisomerase I levels in non–small cell lung cancer cells. Proc Am Assoc Cancer Res 2002; 43: 247 (Аbst. 1227).
16. Homesley HD et al. A dose–escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gyn Oncol 2000; 83: 394–9.
17. Safra T et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gyn Oncol 2007; doi:10.1016/j.ygyno.2006.11.017.
18. Хохлова С.В., Горбунова В.А. Еженедельное введение топотекана: возможность управления токсичностью при сохранении эффективности. Рус. мед. журн. 2009; 13.
19. Zanaboni F, Grijuela B, Kusamura S et al. Weekly topotecan and cisplatin (TOPOCIS) as neoadjuvant chemotherapy for locallyadvanced squamous cervical carcinoma: results of a phase II study. J Clin Oncol 2008; 26 (Suppl.): Abstract 16500.
20. Jaime Coronel et al. Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. Med Oncol 2009; 26: 210–4.
21. Ten Bokkel Huinink W et al. Topotecan versus paclitaxel for the treatment of recurrent epithelian ovarian cancer. J Clin Oncol 1997; 15: 2183–93.
22. James V, Fiorica A. Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: A Gynecologic Oncology Group study. Gyn Oncol 2009; 115: 285–9.
2. Schiffman M, Kjaer SK. Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 14.
3. Онкология. Национальное руководство. Под ред. акад. В.И.Чисова. М.: Гэотар-Медиа, 2008.
4. Fiorica J, Holloway R, Ndubisi B et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gyn Oncol 2002; 85 (1): 89–94.
5. Новик В.И. Эпидемиология рака шейки матки, факторы риска, скрининг. Практ. онкол. 2002; 3 (3).
6. Tiersten AD, Selleck MJ, Hershman DL et al. Phase II study of topotecan and paclitaxel for persistent, or metastatic cervical cancer. Gyn Oncol 2004; 92: 635–8.
7. Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 2003; 9 (5): 425–32 (Review).
8. Thigpen T, Shingleton H, Homesley H et al. Cis-dichlorodiammineplatinum (II) in the treatment of gynecologic malignancies: Phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep 1979; 63: 1549–55.
9. Lorusso D, Pietragalla A, Mainenti S et al. Review role of topotecan in gynaecological cancers: Current indications and perspectives. Crit Rev Oncol Hematol 2009; 17 [Epub ahead of print].
10. McGuire WP, Blessing JA, Bookman MA et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian сarcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 1062–7.
11. Randall-Whitis LM, Monk BJ. Topotecan in the management of cervical cancer. Expert Opin Pharmacother 2007; 8: 227–36.
12. Long HJ 3rd, Bundy Bn, Grendys EC JR et al. Randomized phase III trial of Cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol 2005; 23: 4623–33.
13. Monk BJ, Huang HQ, Cella D et al. Quality of life outcomes from a randomized phase III trial of Cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4617–25.
14. McCabe F et al. Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest 1994; 12: 308–13.
15. Bence A et al. Evaluation of topotecan cytotoxicity and topoisomerase I levels in non–small cell lung cancer cells. Proc Am Assoc Cancer Res 2002; 43: 247 (Аbst. 1227).
16. Homesley HD et al. A dose–escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gyn Oncol 2000; 83: 394–9.
17. Safra T et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gyn Oncol 2007; doi:10.1016/j.ygyno.2006.11.017.
18. Хохлова С.В., Горбунова В.А. Еженедельное введение топотекана: возможность управления токсичностью при сохранении эффективности. Рус. мед. журн. 2009; 13.
19. Zanaboni F, Grijuela B, Kusamura S et al. Weekly topotecan and cisplatin (TOPOCIS) as neoadjuvant chemotherapy for locallyadvanced squamous cervical carcinoma: results of a phase II study. J Clin Oncol 2008; 26 (Suppl.): Abstract 16500.
20. Jaime Coronel et al. Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. Med Oncol 2009; 26: 210–4.
21. Ten Bokkel Huinink W et al. Topotecan versus paclitaxel for the treatment of recurrent epithelian ovarian cancer. J Clin Oncol 1997; 15: 2183–93.
22. James V, Fiorica A. Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: A Gynecologic Oncology Group study. Gyn Oncol 2009; 115: 285–9.
Авторы
Т.В.Харитонова, И.В.Поддубная
Кафедра онкологии ГОУ ДПО РМАПО, Москва
Кафедра онкологии ГОУ ДПО РМАПО, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.